

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**MicroPort Scientific Corporation**

**微創醫療科學有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 00853)**

**POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 18 JUNE 2020  
AND  
RETIREMENT AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

**POLL RESULTS OF THE AGM**

The Board is pleased to announce that all the Proposed Resolutions as set out in the notice of the AGM were duly passed by the Shareholders by way of a poll at the AGM.

**RETIREMENT AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR**

The Board announces that, with effect from the conclusion of the AGM: (i) Mr. Hiroshi Shirafuji has retired as a non-executive Director of the Company; and (ii) Dr. Yasuhisa Kurogi has been elected as a non-executive Director of the Company.

## POLL RESULTS OF THE ANNUAL GENERAL MEETING

The board of directors (the “**Directors**” and the “**Board**”, respectively) of MicroPort Scientific Corporation (the “**Company**”) is pleased to announce that all the proposed ordinary resolutions (the “**Proposed Resolutions**”) as set out in the notice of the annual general meeting (the “**AGM**”) dated 20 May 2020 were duly passed by the holders of the Company’s ordinary shares (the “**Shares**” and the “**Shareholders**” respectively) by way of a poll at the AGM held on 18 June 2020. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive the audited consolidated financial statements and the reports of the Directors and auditor for the year ended 31 December 2019	1,199,629,292 (100.000000%)	0 (0.000000%)
2.	To declare and approve a final dividend of HK5.3 cents (tax inclusive) per Share in the capital of the Company for the year ended 31 December 2019 with an option to elect to receive wholly or partly by an allotment and issue of Shares credited as fully paid in lieu of cash payment	1,199,956,958 (100.000000%)	0 (0.000000%)
3(i).	To re-elect Mr. Norihiro Ashida as a non-executive Director of the Company	1,190,470,537 (99,209437%)	9,486,421 (0.790563%)
3(ii).	To re-elect Mr. Jonathan H. Chou as an independent non-executive Director of the Company	1,191,840,516 (99.323606%)	8,116,442 (0.676394%)
3(iii).	To re-elect Dr. Guoen Liu as an independent non-executive Director of the Company	1,196,971,476 (99.751201%)	2,985,482 (0.248799%)
4.	To elect Dr. Yasuhisa Kurogi as a non-executive Director of the Company	1,199,447,965 (99.957582%)	508,993 (0.042418%)
5.	To authorize the Board to fix the respective Directors’ remuneration	1,196,098,131 (99.993211%)	81,204 (0.006789%)
6.	To re-appoint KPMG as auditor and to authorize the Board to fix their remuneration	1,198,635,003 (99.889833%)	1,321,955 (0.110167%)
7.	To give a general mandate to the Directors to buy back Shares of the Company not exceeding 10% of the total number of issued Shares of the Company as at the date of passing of this resolution	1,199,917,769 (100.000000%)	0 (0.000000%)

8.	To give a general mandate to the Directors to issue, allot and deal with additional Shares of the Company not exceeding 20% of the total number of issued Shares of the Company as at the date of passing of this resolution	996,972,954 (83.086773%)	202,944,815 (16.913227%)
9.	To extend the general mandate granted to the Directors to issue, allot and deal with additional Shares in the capital of the Company by the aggregate number of the Shares bought back by the Company	996,980,675 (83.084703%)	202,976,283 (16.915297%)
10.	To adopt the New Share Option Scheme of the Company	1,100,397,101 (91.727509%)	99,239,857 (8.272491%)
11.	Conditional upon the passing of resolution 10, to terminate the Existing Share Option Scheme of the Company adopted on 3 September 2010	1,100,436,290 (91.730776%)	99,200,668 (8.269224%)

*Notes:*

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 11, all the Proposed Resolutions were duly passed as ordinary resolutions.
- (b) As at the date of the AGM, the total number of Shares of the Company in issue was 1,736,355,940 Shares.
- (c) The total number of Shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 1,736,355,940 Shares.
- (d) There were no Shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (e) No Shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (f) None of the Shareholders of the Company have stated their intention in the Company’s circular dated 20 May 2020 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (g) The Company’s branch share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

## RETIREMENT OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Hiroshi Shirafuji (“**Mr. Shirafuji**”), a non-executive Director of the Company, who did not offer himself for re-election at the AGM in order to allow himself to devote more time to his other endeavours, has retired as a non-executive Director of the Company at the conclusion of the AGM.

Mr. Shirafuji has confirmed that he has no disagreement with the Board and there is no matter in relation to his retirement that needs to be brought to the attention of the Shareholders of the Company.

The Board would like to express its gratitude to Mr. Shirafuji for his valuable efforts and contributions to the Company during his tenure of office.

## APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that, with effect from the conclusion of the AGM, Dr. Yasuhisa Kurogi (“**Dr. Kurogi**”) has been elected as a non-executive Director of the Company. His biographical details are set out below:

Dr. Kurogi, born in 1964, is Head of Business Development of Otsuka Holdings, a substantial Shareholder of the Company currently holding approximately 22.06% of the issued Share capital of the Company. Dr. Kurogi is currently holding directorship in certain subsidiaries of Otsuka Holdings. He is also a director of the Licensing Executive Society JAPAN. Before joining Otsuka Holdings in August 2017, he was a deputy director of Business Development of Otsuka Pharmaceutical Co., Ltd (“OPC”) from 2015 to 2017. From 2007 to 2015, he was responsible for business development at Astex Pharmaceutical, Inc. and OPC. From 1992 to 2007, he was responsible for Research & Development at Cambridge Isotope Laboratories, Inc., Otsuka Maryland Research Laboratory, Inc., OPC, and Otsuka Pharmaceutical Factory, Inc. Dr. Kurogi received his Ph.D. degree in medicinal chemistry from the Hiroshima University in 1992 and was a fellow at Okazaki National Research Institutes in 1990. He also was a visiting lecturer of Tohoku University in 2000.

Save as disclosed above, Dr. Kurogi did not hold any directorship in other listed public companies in Hong Kong or overseas in the last three years, and he is not related to any Directors, senior management, other substantial or controlling Shareholders of the Company (as defined in the Listing Rules) of the Company, nor does he hold any other positions with the Company or any of its subsidiaries.

Dr. Kurogi is not interested or deemed to be interested in any Shares, underlying Shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Dr. Kurogi has entered into a letter of appointment with the Company for a term of three years, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Dr. Kurogi's emolument, if any, will be determined by the Board from time to time under the authority granted to the Board by the Shareholders and in accordance with the recommendation of the remuneration committee of the Board by reference to his experience and responsibilities, the Company's performance, remuneration policy and prevailing market conditions. Dr. Kurogi will also be appointed a member of the Strategic Committee of the Board.

There is no information which is discloseable nor is Dr. Kurogi involved in any of the matters required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning Dr. Kurogi that need to be brought to the attention of the Shareholders.

The Board would like to welcome Dr. Kurogi for joining the Board.

By Order of the Board  
**MicroPort Scientific Corporation**  
**Dr Zhaohua Chang**  
*Chairman*

Shanghai, the People's Republic of China, 18 June 2020

*As at the date of this announcement, the executive Director is Dr. Zhaohua Chang; the non-executive directors are Mr. Norihiro Ashida, Dr. Yasuhisa Kurogi and Mr. Hongliang Yu; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.*

\* *for identification purpose only*